Acute Agitation in Youth With and Without Substance Use: Treatment Patterns and Outcomes Following Intramuscular Antipsychotics

Acute agitation in pediatric patients presents significant challenges in acute psychiatric settings. Substance use may complicate management, yet data examining treatment outcomes in this population remain limited. This study examined whether substance use was associated with differences in presentation characteristics, treatment patterns, and outcomes among youth receiving intramuscular (IM) antipsychotics for agitation. A retrospective review was conducted of pediatric patients who received IM chlorpromazine or haloperidol for acute agitation across a large health system from 2019–2023. Patients were categorized based on documented substance use (positive urine drug screening or clinical documentation). Groups were compared on demographics, clinical characteristics, medication use, repeat IM medication administration, restraint or seclusion, and adverse events. Survival analysis examined time to repeat medication administration, and logistic regression evaluated predictors of adverse vital-sign events. Among 150 patients (mean age 12 years), 47 (31.3%) had documented substance use. Patients with substance use were older (14.1 vs. 11.3 years, p < 0.001), more likely to present with police involvement (40.4% vs. 8.7%, p < 0.001) and be treated in the emergency department (68.1% vs. 48.5%, p = 0.026). Medication selection, benzodiazepine coadministration, restraint or seclusion, repeat IM medication, time to re-administration, and rates of adverse events did not differ between groups. Substance use was associated with differences in the circumstances of presentation, but was not associated with differences in short-term pharmacologic efficacy or safety outcomes among pediatric patients treated with IM antipsychotics for agitation.

Authors

Institutions

Publication Details

Journal
Journal of Child & Adolescent Substance Use
Published
2026-11-12
DOI
https://doi.org/10.1080/29973368.2026.2759621
Primary Topic
Schizophrenia research and treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Acute Agitation in Youth With and Without Substance Use: Treatment Patterns and Outcomes Following Intramuscular Antipsychotics

Timothy Rice, Chaden Noureddine, FRANCES RUDNICK LEVIN, Ricky Burns et al.
Journal of Child & Adolescent Substance Use
Schizophrenia research and treatment
article

Acute Agitation in Youth With and Without Substance Use: Treatment Patterns and Outcomes Following Intramuscular Antipsychotics

Timothy Rice, Chaden Noureddine, FRANCES RUDNICK LEVIN, Ricky Burns, Sean Lynch, Ashley N. Sterchele, Angelo I. Chaia
article en

Abstract

Acute agitation in pediatric patients presents significant challenges in acute psychiatric settings. Substance use may complicate management, yet data examining treatment outcomes in this population remain limited. This study examined whether substance use was associated with differences in presentation characteristics, treatment patterns, and outcomes among youth receiving intramuscular (IM) antipsychotics for agitation. A retrospective review was conducted of pediatric patients who received IM chlorpromazine or haloperidol for acute agitation across a large health system from 2019–2023. Patients were categorized based on documented substance use (positive urine drug screening or clinical documentation). Groups were compared on demographics, clinical characteristics, medication use, repeat IM medication administration, restraint or seclusion, and adverse events. Survival analysis examined time to repeat medication administration, and logistic regression evaluated predictors of adverse vital-sign events. Among 150 patients (mean age 12 years), 47 (31.3%) had documented substance use. Patients with substance use were older (14.1 vs. 11.3 years, p < 0.001), more likely to present with police involvement (40.4% vs. 8.7%, p < 0.001) and be treated in the emergency department (68.1% vs. 48.5%, p = 0.026). Medication selection, benzodiazepine coadministration, restraint or seclusion, repeat IM medication, time to re-administration, and rates of adverse events did not differ between groups. Substance use was associated with differences in the circumstances of presentation, but was not associated with differences in short-term pharmacologic efficacy or safety outcomes among pediatric patients treated with IM antipsychotics for agitation.

Journal of Child & Adolescent Substance Use
Columbia University Irving Medical Center (US), New York State Psychiatric Institute (US), Icahn School of Medicine at Mount Sinai (US)
National Institute on Drug Abuse
Good health and well-being
Schizophrenia research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon